Autolus Therapeutics (AUTL) investor relations material

Recent developments and product differentiation

• Focus on CAR-T therapies with high clinical activity and strong safety profile, aiming for broad patient access in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).

• AUCATZYL (obe-cel) is available in the U.S. and U.K., with ongoing efforts for European market access.

• Real-world data from the Rocket Consortium supports robust efficacy and safety, with a reliable supply chain and high manufacturing success rates.

Market opportunity and patient impact

• U.S. addressable market for relapsed/refractory adult ALL is about 1,800 patients annually, with high unmet medical need.

• Disease progression can severely impact cognition and mobility, highlighting the need for effective therapies.

Efficacy and safety profile

• Pivotal study showed a 78% overall response rate, with 40% of patients in ongoing remission after three years.

• Real-world response rates are even higher at 95%, especially in patients treated earlier in disease progression.

• High-grade cytokine release syndrome was not observed, and only 3% experienced high-grade neurological toxicity, enabling treatment of frail or high-risk patients.